How effective is dupilumab/dalbitux in treating eczema?

Dupilumab(dupilumab) has been widely used in the treatment of moderate to severe eczema (atopic dermatitis) in recent years and is one of the globally recognized representative drugs for "targeted therapy of type II inflammation". For patients with recurrent eczema who are still difficult to control despite long-term dependence on external medications, the emergence of dupilumab provides a more systematic and precise treatment direction. This drug interferes with IL-4 and IL-13 signaling by blocking the IL-4Rα pathway, and can regulate eczema-related immune responses from the source. This is a deep mechanism that is difficult to achieve with traditional anti-inflammatory topical drugs, so it is outstanding in long-term control.

Eczema patients often face problems such as skin barrier damage, persistent itching, and spread of rash. The therapeutic advantage of dupilumab is that it can regulate the immune response at the root of inflammation, thereby helping the skin return to a stable state. After continued use, many patients have gradually reduced symptoms such as dry skin, desquamation, and exudation, reduced nighttime itching, and enhanced skin repair ability. Compared with the uncertainty caused by frequent use of topical hormones, Dalbitux has the advantages of relatively clear long-term use regimen and stable tolerability, and can continue to maintain the treatment rhythm when skin surface symptoms have not completely recurred, thereby helping patients maintain the remission period.

In addition, the overseas clinical application experience of dupilumab shows that it not only improves skin symptoms, but also often improves sleep quality, mental state and overall living ability, which is an easily overlooked but crucial part of the long-term management of eczema. Eczema is a chronic inflammatory disease that cannot be completely resolved by short-term medication alone. As a systemic treatment option, Dalbitux can maintain skin ecological stability over a longer period of time. For some patients with asthma, rhinitis or allergies, the improvement of such "type II inflammatory comorbidities" often results in additional benefits during the treatment process.

Reference materials:https://www.drugs.com